Gunsoo Kim
ㆍ CEO
ㆍ CHA Biotech
ㆍ LG Chem
Jong Ran Kim
ㆍ Executive Vice President
ㆍ Head of Clinical Development Center
ㆍ Samsung Bioepis
Hyeong Cheol Kim, Ph.D.
ㆍ Head of R&D Center
ㆍ Director
ㆍ LG Chem
Jin Kyong Park
ㆍ CFO
ㆍ LG Chem
Hyerim Seo
ㆍ Director
ㆍ SamsungBioepis
ㆍ UCB
ㆍ IQVIA
Hyeun Jin Seo
ㆍ Director
ㆍ ChongKunDang
ㆍ Hanhwa Solution
Mi Kyung Kim, Ph.D.
ㆍ Director
ㆍ Postdoc fellow at NYU Medical Center
Donghyuk Jeon
ㆍ Head of GMP Center
ㆍ Director
ㆍ LG Chem
Suhee Cho
ㆍ Clinical development advisor
ㆍ Director
ㆍPusan National University Yangsan
ㆍHospital Clinical assistant professor
Gunsoo Kim
CEO
Hyung Cheol Kim, Ph.D.
Head of R&D
Jin Kyong Park
CFO
Jung Hee Lim
Non-executive Director
Changwan Hong, Ph.D.
Outside Director
Daniel Ryu
Auditor
Hyun-Bo Sim, Ph.D.
Ewha Womans University Associate Professor
Chanhyuk Kim, Ph.D.
KAIST Assistant Professor
OVIS™ CD19 CAR-T cell therapy targeting DLBCL STICK Ventures, ATINUM Investment, DS Asset Management, SEOUL Investment Partners, IMM Investment, AJU IB Investment, ULMUS Investment, LB Investment, RYUKYUNG PSG Asset Management, E& Venture Partners, JX Partners, COMPANY K Partners, K2 Investment Partners, QUAD Ventures, HANA Ventures Anti-BCMA binding region, a fusion protein comprising the same, and a composition comprising the same, Qurocell et al., No. 10-2020-0031211, filing date 2020.03.13 In Samsung Medical Center Future Medical Center ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME, application number PCT/IB2019/050194, filing date 2019.01.10 Intervest, Mirae Asset Capital, Stick Ventures, Time Folio Function-enhancing immune cells using two types of shRNA and pharmaceutical compositions containing the immune cells, Qurocell et al., 1, Application No. 10-2018-0004238, filing date 2018.01.12 Intervest, Mirae Asset CapitalTimeline
CAR-T cell therapy approved for clinical study from MFDS for the first in Korea
(Code named: CRC01)Attracted investment of Series C 44 billion ￦
Domestic patent application
GMP manufacturing for clinical sample production of immune cell therapy products
Selected as technology transfer commercialization project (investment-linked R&BD) by the Ministry of Science and Technology
Domestic application 10-2018-0004238 PCT application for patent
Signed MOU with Samsung Seoul Hospital for joint research on immunotherapy
Attracted investment of Series B 15 billion ￦
Selected as a regional specialized industry development project by the Small and Medium Venture Business Department
Selected as a base technology construction project for the high-tech medical complex by the Ministry of Health and Welfare
Domestic patent application
Attracted investment of Series A 2 billion ￦
Certified as a company-affiliated research institute and selected as a private investment-led technology start-up support project by the Small and Medium Business Administration (TIPS)
Acquired Venture Business Authorization
CEO Gunsoo Kim inaugurated
Incorporation, business registration
